Secretary Kennedy’s reductions in force, offered as reform, may cripple drug approvals, gut biomedical research, and gamble ...

Revenue (GAAP) rose 20.4% year over year to $1.373 million, beating analyst estimates by nearly three-fold (GAAP revenue was $1.373 million vs. analyst estimate of $0.47 million, a 194.2% beat). Net ...

A recent study reveals that 81% of Indians are using AI tools like ChatGPT and Google AI to manage daily overthinking, ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

Key Points GAAP revenue surpassed expectations, reaching $12.5 million in Q2 2025, Revenue reached $12.5 million, up approximately 45.3% from the prior year period. Net loss (GAAP) widened to $112.0 ...

This market evolution is not a passive trend but a deliberate, competitive push to meet the demands of a high-stakes clinical ...